Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $29.16, but opened at $28.00. Metsera shares last traded at $28.04, with a volume of 95,958 shares changing hands.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on MTSR shares. Guggenheim began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 target price on the stock. Cantor Fitzgerald began coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Evercore ISI assumed coverage on Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Bank of America began coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target on the stock.
Check Out Our Latest Analysis on Metsera
Metsera Stock Up 6.8 %
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- Technology Stocks Explained: Here’s What to Know About Tech
- Archer Aviation Stock Sees Surge in Institutional Buys
- How to Evaluate a Stock Before Buying
- These 4 Stocks Offer High Upside in the AI Data Center Boom
- How to Read Stock Charts for Beginners
- How Can Tomahawk 6 Contribute to Broadcom’s AI Growth Story?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
